The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|June 21, 2022
Rheumatoid Arthritis Quiz: Modifying DMARD Therapy
Author(s)Ingrid Torjesen
Do you know the latest recommendations for managing patients with rheumatoid arthritis who have not achieved target with disease-modifying antirheumatic drugs (DMARDs)? Take this quiz to find out.
Advertisement
Which of the following should be prescribed to patients taking maximally tolerated doses of methotrexate who are not at target?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement